EHMT2 and cholangiocarcinoma: G9a was overexpressed in breast, gastric, ovarian, cervical, endometrial, prostate, lung, colorectal, liver, urinary bladder, and brain cancers, as well as in hematological malignancies, melanoma, and cholangiocarcinoma, leading to aberrant H3K9 methylation [109,110,111,112,113,114,115,116,117,118,119,120,121,122].